CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–#DigitalDrugDesign–Exicure, Inc. (OTCQB: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, is proud to announce Co-founder Chad A. Mirkin has been awarded the $250,000 Kabiller Prize in Nanoscience and Nanomedicine for discovering and developing spherical nucleic acids (SNAs).

SNAs are nanostructures that enable the safe and effective delivery of nucleic acid therapeutics into cells and tissues. The technology originated in Mirkin’s laboratory at the Northwestern University International Institute for Nanotechnology, where he is a professor.

The $250,000 Kabiller Prize is the largest monetary award in the world for outstanding achievement in the field of nanotechnology and its application to medicine and biology.

Exicure’s lead programs utilize proprietary SNA technology to address inflammatory diseases, genetic disorders and oncology.

Using SNA technology to mobilize the body’s natural defense against cancer, Exicure’s lead immunotherapy compound, AST-008 (initially being investigated in selected solid and hematological tumors) is a toll-like receptor 9 agonist designed to utilize the SNA’s beneficial properties to drive a potent anti-cancer immune response. The treatment could accompany other systemic therapies while driving a stronger immune response than other technologies. Learn more about the AST-008 clinical trial at the U.S. FDA Clinical Trial Registry website.

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. We believe Exicure’s proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure’s lead program is in a Phase1b/2 trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL. www.exicuretx.com

Forward Looking Statements

This press release contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning the Company, the Company’s technology, potential therapies, cash requirements and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: unexpected costs, charges or expenses that reduce cash runway; that Exicure’s pre-clinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the cost, timing and results of clinical trials; that many drug candidates that have completed Phase 1 trials do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; regulatory developments; and the ability of Exicure to protect its intellectual property rights. Risks facing the Company and its programs are set forth in the Company’s filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement (including without limitation its cash runway guidance) or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

MacDougall

Karen Sharma

781-235-3060

[email protected]

CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–#DigitalDrugDesign–Exicure, Inc. (OTCQB: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, is proud to announce Co-founder Chad A. Mirkin has been awarded the $250,000 Kabiller Prize in Nanoscience and Nanomedicine for discovering and developing spherical nucleic acids (SNAs).

SNAs are nanostructures that enable the safe and effective delivery of nucleic acid therapeutics into cells and tissues. The technology originated in Mirkin’s laboratory at the Northwestern University International Institute for Nanotechnology, where he is a professor.

The $250,000 Kabiller Prize is the largest monetary award in the world for outstanding achievement in the field of nanotechnology and its application to medicine and biology.

Exicure’s lead programs utilize proprietary SNA technology to address inflammatory diseases, genetic disorders and oncology.

Using SNA technology to mobilize the body’s natural defense against cancer, Exicure’s lead immunotherapy compound, AST-008 (initially being investigated in selected solid and hematological tumors) is a toll-like receptor 9 agonist designed to utilize the SNA’s beneficial properties to drive a potent anti-cancer immune response. The treatment could accompany other systemic therapies while driving a stronger immune response than other technologies. Learn more about the AST-008 clinical trial at the U.S. FDA Clinical Trial Registry website.

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. We believe Exicure’s proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure’s lead program is in a Phase1b/2 trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL. www.exicuretx.com

Forward Looking Statements

This press release contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning the Company, the Company’s technology, potential therapies, cash requirements and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: unexpected costs, charges or expenses that reduce cash runway; that Exicure’s pre-clinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the cost, timing and results of clinical trials; that many drug candidates that have completed Phase 1 trials do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; regulatory developments; and the ability of Exicure to protect its intellectual property rights. Risks facing the Company and its programs are set forth in the Company’s filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement (including without limitation its cash runway guidance) or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

MacDougall

Karen Sharma

781-235-3060

[email protected]